Portfolio Companies

Achillion
New Haven, CT
Innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease
ACQUIRED BY ALEXION IN JANUARY 2020
Amicus
(NASDAQ: FOLD)
Cranbury, NJ
Developing small molecule, orally active drugs to treat lysosomal storage disorders using pharmacological chaperones to selectively bind and "rescue" misfolded target proteins
BioRexis
King of Prussia, PA
Uses a proprietary protein engineering platform and a modified form of transferrin to enhance half life, efficacy, and safety of proteins; initially targeting diabetes
Acquired by Pfizer in February 2007
Celator
Princeton, NJ
Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers
ACQUIRED BY JAZZ PHARMACEUTICALS IN JULY 2016
Cellatope
Philadelphia, PA
Uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases
ACQUIRED BY CYPRESS BIOSCIENCE IN FEBRUARY 2009
Diasome
Conshohocken, PA
Uses Hepatocyte Directed Vesicles to deliver insulin for diabetes treatment
Durata
Chicago, IL
Developing drugs to advance care in infectious disease, including Gram-positive acute bacterial skin and skin structure infections (abSSSI)
ACQUIRED BY ACTIVAS IN NOVEMBER 2014
EKR
Bedminster, NJ
Specialty pharma company focused on the acute care setting, treating conditions in cardiology, thrombolytic, and oncology supportive care areas
ACQUIRED BY CORNERSTONE THERAPEUTICS IN JUNE 2012
Horizon
(NASDAQ: HZNP)
Deerfield, IL
Identifying, developing, acquiring and commercializing drugs to target unmet therapeutic needs in arthritis, pain, inflammatory and rare diseases
Insmed
(NASDAQ: INSM)
Monmouth Jct., NJ
Developing inhaled therapeutics to treat chronic respiratory infections, with additional programs for treatment of neuromuscular and metabolic disorders
Intact
Wayne, PA
Medical device company developing a novel endovascular stapling device designed to optimize peripheral angioplasty results for the treatment of peripheral artery disease (PAD)
ACQUIRED BY PHILIPS IN SEPTEMBER 2020
Medmark
Pittsburgh, PA
Specialty pharmaceutical distributor, focused on high-cost injectables and infusibles that require special handling and strict adherence to prescribed treatment protocols
Acquired by Walgreen Co. in July 2006
Melinta
New Haven, CT
Developing and commercializing novel antibiotics that provide new and better therapeutic solutions to treat bacterial infections.
Neuronetics
(NASDAQ: STIM)
Malvern, PA
Developing and commercializing Transcranial Magnetic Stimulation, a noninvasive medical technology, to treat psychiatric and neurological disorders
Nupathe
Malvern, PA
Specialty pharma company developing innovative products for the treatment of neurologic and psychiatric diseases
ACQUIRED BY TEVA PHARMACEUTICALS IN FEBRUARY 2014
Precision Derm
New York, NY
Integrated dermatology company commercializing prescription and consumer skincare products
ACQUIRED BY VALEANT PHARMACEUTICALS IN JULY 2014
Protez
Malvern, PA
Developing small molecule antibiotics to address increasing bacterial resistance and chronic or recurrent infections
Acquired by Novartis AG in July 2008
RainDance
Billerica, MA
Provider of innovative single molecule and single cell analysis solutions that enable discovery of common and rare regions of genomic interest. Proprietary microdroplet technology has broad applications in genomic research, development of clinical diagnostics, compound screening, and biomarker detection
ACQUIRED BY BIO-RAD IN FEBRUARY 2017
Tobira
South San Francisco, CA
Developing and commercializing therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV
ACQUIRED BY ALLERGAN IN NOVEMBER 2016
TranEnterix
Durham, NC
Developing and commercializing revolutionary robotics to improve minimally invasive surgery by addressing clinical and economic challenges associated with current options.
TearScience
Morrisville, NC
Commercializing a novel, office-based medical device to identify, diagnose and treat Meibomian Gland Dysfunction, the leading cause of dry eye
ACQUIRED BY ABBOTT MEDICAL OPTICS IN SEPTEMBER 2017